Clinical predictors of screen-defined dementia in early Parkinson’s
Objective: Predicting early dementia in Parkinson’s disease (PD) has important implications for individual prognosis, designing clinical trials and targeting novel treatments, but there remains a…Exploring the relationship between motor impairment, vascular burden and cognition in Parkinson’s disease
Objective: To determine frequency and type of cognitive disorders in cross-sectional analysis of a Parkinson’s disease (PD) cohort, and explore its relations to motor symptoms,…FDG-PET and metabolomics in PD-associated GBA variants
Objective: To assess the clinical, cognitive, metabolic, and imaging phenotypes of PD patients carrying the variants p.E365K and p.T408M in the GBA gene (NM_000157.3). Background:…MANF improves the MPP+/MPTP-induced Parkinson’s disease via improvement of mitochondrial function and inhibition of oxidative stress
Objective: This study aimed to investigate the therapeutic effect of mesencephalic astrocyte-derived neurotrophic factor (MANF) on the MPTP/MPP+-induced model of Parkinson's disease (PD) and the…Expanding the canvas of PARKIN mutations and clinical phenotypes in familial and early onset Parkinson’s disease patients
Objective: To identify PARKIN mutations in PD patients with familial history (FPD) and early onset PD patients with no family history (EOPD; ≤50 years) and…BDNF(V66M), EIF4G1(R1205H), VPS35(D620N) gene polymorphisms in South Indian PD Patients
Objective: To investigate the association of BDNF(V66M), EIF4G1(R1205H) and VPS35(D620N) polymorphisms in South Indian PD patients. Background: Parkinson’s disease (PD) is the most common form…Diagnostic utility of a targeted resequencing technique of next generation sequencing in detecting copy number changes in PARK2
Objective: We investigate feasibility of Next Generation Sequencing (NGS) targeted sequencing technique using Ampliseq® technology by Ion PGM® to detect copy number variation mutation in…Levels of plasma alpha-synuclein as measured using Single Molecule Array technology is higher in Parkinson’s disease compared to controls and is not influenced by LRRK2 genotype
Objective: To investigate plasma alpha-synuclein levels in PD using ultra-sensitive protein detection technology, and to determine the association of plasma alpha-synuclein with cognitive, motor and…DAT-imaging and clinical phenotypes of Parkinson’s disease
Objective: To evaluate the relationship of motor and nonmotor symptoms with striatal dopaminergic denervation in a cohort of symptomatic PD patients with positive DAT-imaging Background:…Quantitative analysis of DaT uptake and neuromelanin MR contrast in patients with Parkinson’s disease and healthy controls
Objective: To examined quantitative measures of neuromelanin (NM) MRI and DaT-SPECT imaging of the SN and striatum to distinguish PD patients from healthy control subjects…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 177
- Next Page »